Labcorp Holdings Inc. $LH Stock Holdings Reduced by Barry Investment Advisors LLC

Barry Investment Advisors LLC lowered its position in Labcorp Holdings Inc. (NYSE:LH) by 4.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,421 shares of the medical research company’s stock after selling 120 shares during the quarter. Barry Investment Advisors LLC’s holdings in Labcorp were worth $636,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. MassMutual Private Wealth & Trust FSB raised its holdings in Labcorp by 10.2% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 433 shares of the medical research company’s stock valued at $114,000 after acquiring an additional 40 shares in the last quarter. Wedmont Private Capital raised its holdings in Labcorp by 5.0% in the 1st quarter. Wedmont Private Capital now owns 920 shares of the medical research company’s stock valued at $204,000 after acquiring an additional 44 shares in the last quarter. Dorsey & Whitney Trust CO LLC raised its holdings in Labcorp by 1.4% in the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 3,341 shares of the medical research company’s stock valued at $778,000 after acquiring an additional 45 shares in the last quarter. Tempus Wealth Planning LLC raised its holdings in Labcorp by 2.0% in the 2nd quarter. Tempus Wealth Planning LLC now owns 2,337 shares of the medical research company’s stock valued at $613,000 after acquiring an additional 45 shares in the last quarter. Finally, Horizon Investments LLC raised its holdings in Labcorp by 4.2% in the 1st quarter. Horizon Investments LLC now owns 1,196 shares of the medical research company’s stock valued at $278,000 after acquiring an additional 48 shares in the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Wall Street Analyst Weigh In

LH has been the subject of several recent research reports. Evercore ISI upped their price target on Labcorp from $285.00 to $300.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Morgan Stanley increased their target price on Labcorp from $283.00 to $306.00 and gave the stock an “overweight” rating in a report on Friday, July 25th. UBS Group increased their target price on Labcorp from $282.00 to $305.00 and gave the stock a “buy” rating in a report on Friday, July 25th. Hsbc Global Res cut Labcorp from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Finally, Barclays reissued a “cautious” rating on shares of Labcorp in a report on Wednesday, June 25th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $290.33.

Labcorp Price Performance

Labcorp stock opened at $280.87 on Friday. The business’s fifty day moving average is $271.17 and its two-hundred day moving average is $253.08. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.32 and a current ratio of 1.50. The firm has a market cap of $23.34 billion, a P/E ratio of 31.00, a P/E/G ratio of 1.79 and a beta of 0.85. Labcorp Holdings Inc. has a 52 week low of $209.38 and a 52 week high of $283.47.

Labcorp (NYSE:LH) last announced its earnings results on Thursday, July 24th. The medical research company reported $4.35 earnings per share for the quarter, beating analysts’ consensus estimates of $4.14 by $0.21. Labcorp had a return on equity of 15.45% and a net margin of 5.66%.The company had revenue of $3.53 billion during the quarter, compared to analyst estimates of $3.49 billion. During the same period last year, the company posted $3.94 earnings per share. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. Labcorp has set its FY 2025 guidance at 16.050-16.500 EPS. Equities research analysts forecast that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 11th. Shareholders of record on Thursday, August 28th were given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Thursday, August 28th. Labcorp’s dividend payout ratio (DPR) is presently 31.79%.

Insider Transactions at Labcorp

In other Labcorp news, Director Kerrii B. Anderson sold 3,500 shares of the stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $280.00, for a total value of $980,000.00. Following the transaction, the director directly owned 8,666 shares in the company, valued at approximately $2,426,480. This trade represents a 28.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 3,903 shares of the stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $271.42, for a total value of $1,059,352.26. Following the completion of the transaction, the executive vice president owned 2,274 shares in the company, valued at $617,209.08. The trade was a 63.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,546 shares of company stock valued at $4,207,192 over the last 90 days. 0.84% of the stock is currently owned by corporate insiders.

About Labcorp

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.